Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.immuni.2020.03.007 http://scihub22266oqcxt.onion/10.1016/j.immuni.2020.03.007 32259480!7136867!32259480     free     free     free       Immunity 2020 ; 52 (4): 583-589 Nephropedia Template TP {{tp|p=32259480|t=2020. SARS-CoV-2 Vaccines: Status Report |pdf=|usr=}}{{32259480}} gab.com Text SARS-CoV-2 Vaccines: Status Report JO: Immunity http://www.kidney.de/pget.php?&tw=1&pmid=32259480 #FOAvip SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population. Twit Text FOAVip SARS-CoV-2 Vaccines: Status Report ????Immunity http://www.kidney.de/pget.php?&tw=1&pmid=32259480 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32259480 #FOAvip English Wikipedia <ref>{{Cite pmid|32259480}}</ref> SARS-CoV-2 Vaccines: Status Report #MMPMID32259480 Amanat F; Krammer F Immunity 2020[Apr]; 52 (4): 583-589 PMID32259480show ga SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population. |*Drug Development[MESH] |*Viral Vaccines/therapeutic use[MESH] |Animals[MESH] |Betacoronavirus/immunology/*pathogenicity[MESH] |COVID-19[MESH] |COVID-19 Vaccines[MESH] |China[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/epidemiology/*prevention & control[MESH] |Coronavirus/pathogenicity[MESH] |Disease Models, Animal[MESH] |Humans[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/epidemiology/*prevention & control[MESH] |SARS-CoV-2[MESH]SARS-CoV-2 Vaccines: Status Report (epmc).pdf DeepDyve Pubget Overpricing